公开(公告)号：AU2021232813A1

公开(公告)日：2021-10-14

申请号：AU2021232813

申请日：2021-09-17

Applicant: VERTEX PHARMA

Inventor： ABDUL-MANAN NORZEHAN ,  NEWSOME DAVID A ,  ZWAHLEN JACQUE

IPC: C07D401/14 ,  C12N15/10

Abstract: Abstract Methods of editing a target genomic region(s), methods of repairing of a DNA break via a HDR pathway, methods of inhibiting or suppressing repair of a DNA break via a NHEJ pathway, and methods of modifying expression of a gene(s) or protein(s) comprise administering to one or more cells that include one or more target genomic regions, a genome editing system and a DNA protein-kinase (DNAPK) inhibitor disclosed herein. Kits and compositions for editing a target gene comprise a genome editing system and a DNAPK inhibitor disclosed herein.

公开(公告)号：CA3038657A1

公开(公告)日：2018-04-05

申请号：CA3038657

申请日：2017-09-27

Applicant: VERTEX PHARMA

Inventor： BOUCHER DIANE M ,  HILLIER SHAWN M ,  TSAI WANJUNG ,  HARE BRIAN ,  MARKLAND WILLIAM ,  NEWSOME DAVID A ,  PENNEY MARINA S

IPC: A61K31/506 ,  C07B59/00 ,  C07D401/14

Abstract: Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R1, Q, Ring A, and Ring B are as defined herein.

公开(公告)号：MX394860B

公开(公告)日：2025-03-24

申请号：MX2019003317

申请日：2019-03-22

Applicant: VERTEX PHARMA

Inventor： HARE BRIAN ,  NEWSOME DAVID A ,  BOUCHER DIANE M ,  PENNEY MARINA S ,  HILLIER SHAWN M ,  TSAI WANJUNG ,  MARKLAND WILLIAM

IPC: A61K31/506 ,  C07B59/00 ,  C07D401/14

Abstract: En la presente invención de describen métodos para tratar una enfermedad proliferativa en un sujeto al administrar un agente que daña ADN y entre aproximadamente 8 y aproximadamente 48 horas después, administrar al sujeto un inhibidor de ADN-PK. Los inhibidores de ADN-PK ejemplares están representados por la fórmula (B-I): y por sales farmacéuticamente aceptables de los mismos, en donde R1, Q, el anillo A y el anillo B son como se definen en la presente.

公开(公告)号：MA45670A

公开(公告)日：2019-05-22

申请号：MA45670

申请日：2017-07-13

Applicant: VERTEX PHARMA

Inventor： ABDUL-MANAN NORZEHAN ,  NEWSOME DAVID A ,  ZWAHLEN JACQUE

IPC: C07D401/14 ,  C12N15/10

公开(公告)号：AU2017335648A1

公开(公告)日：2019-04-11

申请号：AU2017335648

申请日：2017-09-27

Applicant: VERTEX PHARMA

Inventor： BOUCHER DIANE M ,  HILLIER SHAWN M ,  TSAI WANJUNG ,  HARE BRIAN ,  MARKLAND WILLIAM ,  NEWSOME DAVID A ,  PENNEY MARINA S

IPC: C07D401/14 ,  A61K31/506 ,  C07B59/00

Abstract: Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R

公开(公告)号：AU2017295720B2

公开(公告)日：2021-07-22

申请号：AU2017295720

申请日：2017-07-13

Applicant: VERTEX PHARMA

Inventor： ABDUL-MANAN NORZEHAN ,  NEWSOME DAVID A ,  ZWAHLEN JACQUE

IPC: C07D401/14 ,  C12N15/10

Abstract: Methods of editing a target genomic region(s), methods of repairing of a DNA break via a HDR pathway, methods of inhibiting or suppressing repair of a DNA break via a NHEJ pathway, and methods of modifying expression of a gene(s) or protein(s) comprise administering to one or more cells that include one or more target genomic regions, a genome editing system and a DNA protein-kinase (DNAPK) inhibitor disclosed herein. Kits and compositions for editing a target gene comprise a genome editing system and a DNAPK inhibitor disclosed herein.

公开(公告)号：CA3030783A1

公开(公告)日：2018-01-18

申请号：CA3030783

申请日：2017-07-13

Applicant: VERTEX PHARMA

Inventor： ABDUL-MANAN NORZEHAN ,  NEWSOME DAVID A ,  ZWAHLEN JACQUE

IPC: C07D401/14 ,  C12N15/10

Abstract: Methods of editing a target genomic region(s), methods of repairing of a DNA break via a HDR pathway, methods of inhibiting or suppressing repair of a DNA break via a NHEJ pathway, and methods of modifying expression of a gene(s) or protein(s) comprise administering to one or more cells that include one or more target genomic regions, a genome editing system and a DNA protein-kinase (DNAPK) inhibitor disclosed herein. Kits and compositions for editing a target gene comprise a genome editing system and a DNAPK inhibitor disclosed herein.

公开(公告)号：AU2017335648B2

公开(公告)日：2022-02-17

申请号：AU2017335648

申请日：2017-09-27

Applicant: VERTEX PHARMA

Inventor： BOUCHER DIANE M ,  HILLIER SHAWN M ,  TSAI WANJUNG ,  HARE BRIAN ,  MARKLAND WILLIAM ,  NEWSOME DAVID A ,  PENNEY MARINA S

IPC: A61K31/506 ,  C07B59/00 ,  C07D401/14

Abstract: Described herein are methods of treating a proliferative disease in a subject by administering a DNA-damaging agent and between about 8 and about 48 hours later administering to the subject a DNA-PK inhibitor. Exemplary DNA-PK inhibitors are represented by Formula (B-I): and by pharmaceutically acceptable salts thereof, wherein R

公开(公告)号：RU2758669C2

公开(公告)日：2021-11-01

申请号：RU2019112863

申请日：2017-09-27

Applicant: VERTEX PHARMA

Inventor： BOUCHER DIANE M ,  HILLIER SHAWN M ,  TSAI WANJUNG ,  HARE BRIAN ,  MARKLAND WILLIAM ,  NEWSOME DAVID A ,  PENNY MARINA S

IPC: A61K31/506 ,  A61K31/704 ,  A61P35/00

Abstract: Изобретениеотноситсяк областимедициныи фармацевтики, аименнок способулеченияпролиферативногорасстройствау субъекта, которыйвключаетвведениесубъектуДНК-поражающегоагентаи введениесубъектуингибитораДНК-зависимойпротеинкиназы (ДНК-ПК) втечениеот 8 до 48 часовпослевведенияДНК-поражающегоагента, причемДНК-поражающимагентомявляетсядоксорубициновыйагент; пролиферативноерасстройствопредставляетсобойрак, выбранныйизгруппы, состоящейизнемелкоклеточногоракалегкого, мелкоклеточногоракалегкого, ракапрямойи ободочнойкишки, ракамолочнойжелезы, печеночно-клеточнойкарциномы, ракаэндометрияи ракаяичников; ингибиторомДНК-ПКявляетсясоединение, выбранноеизсоединенияВ-1 или B-2, илиегофармацевтическиприемлемаясоль, илисокристалл, содержащийсоединение B-1 илиегофармацевтическиприемлемуюсольилисоединение B-2 илиегофармацевтическиприемлемуюсольи образовательсокристалла, выбранныйизадипиновой, лимонной, фумаровой, малеиновой, янтарнойи бензойнойкислоты. Техническийрезультатзаключаетсяв эффективностивведенияингибитораДНК-ПКв течениеот 8 до 48 часовпослевведенияДНК-поражающегоагентаприлечениипролиферативныхзаболеваний. 32 з.п. ф-лы, 29 ил., 27 табл., 10 пр.

公开(公告)号：AU2017295720A1

公开(公告)日：2019-02-07

申请号：AU2017295720

申请日：2017-07-13

Applicant: VERTEX PHARMA

Inventor： ABDUL-MANAN NORZEHAN ,  NEWSOME DAVID A ,  ZWAHLEN JACQUE

IPC: C07D401/14 ,  C12N15/10

Abstract: Methods of editing a target genomic region(s), methods of repairing of a DNA break via a HDR pathway, methods of inhibiting or suppressing repair of a DNA break via a NHEJ pathway, and methods of modifying expression of a gene(s) or protein(s) comprise administering to one or more cells that include one or more target genomic regions, a genome editing system and a DNA protein-kinase (DNAPK) inhibitor disclosed herein. Kits and compositions for editing a target gene comprise a genome editing system and a DNAPK inhibitor disclosed herein.